NONPARAMETRIC INFERENCE PROCEDURE FOR PERCENTILES OF THE RANDOM EFFECTS DISTRIBUTION IN META-ANALYSIS.

To investigate whether treating cancer patients with erythropoiesis-stimulating agents (ESAs) would increase the mortality risk, Bennett et al. [Journal of the American Medical Association299 (2008) 914-924] conducted a meta-analysis with the data from 52 phase III trials comparing ESAs with placebo or standard of care. With a standard parametric random effects modeling approach, the study concluded that ESA administration was significantly associated with increased average mortality risk. In this article we present a simple nonparametric inference procedure for the distribution of the random effects. We re-analyzed the ESA mortality data with the new method. Our results about the center of the random effects distribution were markedly different from those reported by Bennett et al. Moreover, our procedure, which estimates the distribution of the random effects, as opposed to just a simple population average, suggests that the ESA may be beneficial to mortality for approximately a quarter of the study populations. This new meta-analysis technique can be implemented with study-level summary statistics. In contrast to existing methods for parametric random effects models, the validity of our proposal does not require the number of studies involved to be large. From the results of an extensive numerical study, we find that the new procedure performs well even with moderate individual study sample sizes.

[1]  Kurex Sidik,et al.  A simple confidence interval for meta‐analysis , 2002, Statistics in medicine.

[2]  Mitchell J. Mergenthaler.  Nonparametrics: Statistical Methods Based on Ranks , 1979 .

[3]  Ingram Olkin,et al.  A bivariate beta distribution , 2003 .

[4]  Tianxi Cai,et al.  Semiparametric Mixed-Effects Models for Clustered Failure Time Data , 2002 .

[5]  Wolfgang Viechtbauer,et al.  Confidence intervals for the amount of heterogeneity in meta‐analysis , 2007, Statistics in medicine.

[6]  Kurex Sidik,et al.  A comparison of heterogeneity variance estimators in combining results of studies , 2007, Statistics in medicine.

[7]  Sarah E Brockwell,et al.  A simple method for inference on an overall effect in meta‐analysis , 2007, Statistics in medicine.

[8]  Chukiat Viwatwongkasem,et al.  Some general points in estimating heterogeneity variance with the DerSimonian-Laird estimator. , 2002, Biostatistics.

[9]  Julian P T Higgins,et al.  Recent developments in meta‐analysis , 2008, Statistics in medicine.

[10]  J. Hartung,et al.  A refined method for the meta‐analysis of controlled clinical trials with binary outcome , 2001, Statistics in medicine.

[11]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[12]  Sarah E. Brockwell,et al.  A comparison of statistical methods for meta‐analysis , 2001, Statistics in medicine.

[13]  R Henderson,et al.  Joint modelling of longitudinal measurements and event time data. , 2000, Biostatistics.

[14]  Donglin Zeng,et al.  Maximum likelihood estimation in semiparametric regression models with censored data , 2007, Statistica Sinica.

[15]  Frederick Mosteller,et al.  A modified random-effect procedure for combining risk difference in sets of 2×2 tables from clinical trials , 1993 .

[16]  N M Laird,et al.  Mixture models for the joint distribution of repeated measures and event times. , 1997, Statistics in medicine.

[17]  Joachim Hartung,et al.  An Alternative Method for Meta‐Analysis , 1999 .

[18]  Lu Tian,et al.  Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction. , 2009, Biostatistics.

[19]  B J Biggerstaff,et al.  Incorporating variability in estimates of heterogeneity in the random effects model in meta-analysis. , 1997, Statistics in medicine.

[20]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[21]  D. Dorr,et al.  Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. , 2008, JAMA.

[22]  J. Nelder,et al.  Generalized Linear Models with Random Effects: Unified Analysis via H-likelihood , 2006 .

[23]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[24]  Xihong Lin,et al.  SEMIPARAMETRIC TRANSFORMATION MODELS WITH RANDOM EFFECTS FOR CLUSTERED FAILURE TIME DATA. , 2008, Statistica Sinica.

[25]  Changbao Wu,et al.  Jackknife, Bootstrap and Other Resampling Methods in Regression Analysis , 1986 .

[26]  S. Thompson,et al.  Detecting and describing heterogeneity in meta-analysis. , 1998, Statistics in medicine.

[27]  P. Hougaard,et al.  Frailty models for survival data , 1995, Lifetime data analysis.

[28]  S G Thompson,et al.  A likelihood approach to meta-analysis with random effects. , 1996, Statistics in medicine.

[29]  Modeling Multivariate Survival Data by a Semiparametric Random Effects Proportional Odds Model , 2002, Biometrics.

[30]  Geert Molenberghs,et al.  Random Effects Models for Longitudinal Data , 2010 .

[31]  J. Hartung,et al.  On tests of the overall treatment effect in meta‐analysis with normally distributed responses , 2001, Statistics in medicine.

[32]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[33]  M. Karim.  Generalized Linear Models With Random Effects , 1991 .

[34]  Raghu Kacker,et al.  Random-effects model for meta-analysis of clinical trials: an update. , 2007, Contemporary clinical trials.